Antibody discovery made simple Novel monoclonal, bispecific, and trispecific antibodies — discovered, optimized, and ready to fuel your pipeline.

High-quality antibody discovery and engineering solutions that turn your ideas into development candidates.

Explore our services Get in touch
New at World ADC 2026: Trispecific ADC data and 52 Views of Cancer

At the 17th World ADC Conference in San Diego, Invenra presented new preclinical data on two T-Body™ trispecific ADC programs and launched 52 Views of Cancer, a playing card deck with original artwork by a cancer patient, survivor, or family member.

See the ADC data » Explore the 52 Views deck »

We find the best antibodies, characterize them, and hand you the best solution.

>0k

Molecules built to date

0%+

Expected purity for lead candidates

0+

Partners

2

Molecules in the clinic

Plug-and-play multispecific antibody development. Exceptional quality. Transparent terms.

Most antibody platforms push engineering complexity into the variable domains, so every new molecule brings new chain pairing, purification, and manufacturing risk. If a lead fails late for something that should have been caught early, you’re back to zero.

Our B-Body® and T-Body™ platforms solve the hard engineering in the constant domains, so your variable domains plug in and go.

About B-Body About T-Body
Screen hundreds of combinations in the final therapeutic format.
Ready for CLD and CMC.
Transparent pricing, clear path to licensing, and straight-forward agreements.
What this means in practice

Screen 288+ bispecific combinations in one campaign, not just a handful

>99% of combinations pass purity and yield criteria in the B-Body 1x1 format in at least one orientation

Every molecule screened in the final format, so there’s no reformatting later

Standard mAb-like purification processes allowing same process from discovery through manufacturing

Three molecule types. Start where your program is.

Pick the service that matches your target biology. Each path offers Discovery (we find the antibodies) or Expression (you bring the variable domains).

Compare all services »
MONOCLONAL ANTIBODIES Start with mAbs

Novel mAbs or building blocks for a future multispecific program. Fully human, no animals required.

Discovery 2-15 Leads Catalog Coming Soon!
B-BODY® BISPECIFICS Build bispecifics

Screen 288+ Fab arm combinations directly in the final format.

Discovery 2-15 Leads Express Your Sequences
T-BODY™ TRISPECIFICS Engage 3 targets

No VHHs, scFvs, or common light chains required. Unlocks novel mechanisms of action.

Discovery Partner With Us Platform See the Science

Characterization & Validation We don't just make the molecule, we prepare you for what comes next.

Invenra's expertise enables development of drug candidates with the physical and biological characterization needed to support manufacturability and clinical studies.

See all add-on services
Cell Binding Example

BIO

Full biophysical + binding suite

Carterra LSA high-throughput binding kinetics and epitope diversity, validated cell binding analysis, in silico liability scanning, mass spec for intact mass confirmation, full developability assay panel, and high-concentration formulation optimization.

devreport-card

DEV

Extensive developability capabilities

Expression and purity, thermal stability, self-association, aggregation, solubility, immunogenicity risk, viscosity, each measured with a validated technique. The full developability data sits behind every lead candidate we hand off.

Why Invenra What makes us different in antibody development

High purity & yield

The platform just works.

In a single experiment, we tested 144 commercial-stage antibody combinations in both orientations using the B-Body platform. Over 99% passed purity and yield specs in at least one orientation.

Clear pricing

See the numbers on the page.

Transparent terms and pricing. No milestones and royalties for mAb and B-Body projects.

3 targets

Innovative trispecific platform

Developability, functional assays, and binding kinetics are available as add-ons at any stage.

Work with the experts

Add a band of experienced antibody engineers to your team.

We know the platform inside and out. 

HeartsA_2497853616775108489_5284364185457893928

52 views of cancer

First in class trispecific ADC molecules

Our 52 views project goes beyond developing trispecific ADCs and making these novel therapeutics available to partners. We are creating a one-of-a-kind playing card deck that celebrates the creativity, resilience, and spirit of people whose lives have been touched by cancer. Each of the 52 cards will feature original artwork from a cancer patient, survivor, or immediate family member, making every card a unique view of the human experience with this disease.

Explore the 52 Views Deck Discuss a partnership
roland-green
Roland Green CEO and Founder, Invenra

From the beginning, we have always striven to be Best in Class. When we developed the B-Body platform, we kept innovating until we outperformed all the known competitors. The same is true for our T-Body platform. And when you start with an excellent platform, it makes everything else easier."

Program Spotlights A growing list of satisfied scientists

Ronnekleiv-Kelly_Sean_400px-1
Sean Ronnekleiv-Kelly, MDSurgical Oncology, University of Wisconsin SMPH

“The team at Invenra is highly professional, timely with milestones, demonstrate clear expertise and scientific rigor, and offer an extraordinarily unique platform that has yielded high-confidence results, despite an exceedingly challenging target.”

headshot
Ravi V. Kolla, PhDImmunologist and B.D. Professional

“Invenra and its technology are top-notch. I have and will continue to recommend the Invenra team to anyone seeking novel antibody discovery, bispecific and trispecific antibody development, and novel ADC development.”

inv-Avatar
CEOStartup in Stealth Mode

"Top-tier platform combined with top-tier people. A team that has collaborated to drive our programs forward with speed and scientific rigor, even providing services like specialized in vitro assays and efficacy models."

inv-Avatar
CEOStartup in Stealth Mode

"The level of customization and partnership support is unparalleled relative to the other groups we evaluated for our company."

inv-Avatar
VP R&DTop-Tier CDMO

“We have worked with over 20 platforms, and the B-Body was the highest-yielding, easiest to work with bispecific platform.”

Get StartedQuestions or just want to get in touch?

New to Invenra or want to discuss your research program? Fill out the form to get in touch with one of our experts. We’ll get back to you within one business day.

Your information is 100% confidential.

We don’t share your data with third parties, add you to marketing lists without permission, or contact you about anything other than this request. If your program requires an NDA, just say so. We can send one first if you’d like.